Cargando…

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population

PURPOSE: Antiangiogenic tyrosine kinase inhibitors have been the mainstay first-line therapy for metastatic renal cell carcinoma (mRCC). We reviewed the efficacy of first-line therapy with sunitinib in patients with mRCC in an Arab population. METHODS: Medical records of patients with mRCC treated a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Badran, Ahmed, Elshenawy, Mahmoud A., Shahin, Amgad, Aljubran, Ali, Alzahrani, Ahmed, Eldali, Abdelmoneim, Bazarbashi, Shouki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998020/ https://www.ncbi.nlm.nih.gov/pubmed/32031432 http://dx.doi.org/10.1200/JGO.19.00111

Ejemplares similares

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
por: Elshenawy, Mahmoud A., et al.
Publicado: (2020)

Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
por: Bazarbashi, Shouki, et al.
Publicado: (2023)

The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-Line Chemotherapy
por: Bazarbashi, Shouki, et al.
Publicado: (2019)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
por: Aljubran, Ali, et al.
Publicado: (2019)

Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia
por: Alshamsan, Bader, et al.
Publicado: (2023)

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
por: Bazarbashi, Shouki, et al.
Publicado: (2015)

Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy
por: Bazarbashi, Shouki, et al.
Publicado: (2022)

Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience
por: Aseafan, Mohamed, et al.
Publicado: (2022)

Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial
por: Bazarbashi, Shouki, et al.
Publicado: (2022)

Elicitation of Health Utilities in Oncology in the Kingdom of Saudi Arabia
por: Iskedjian, Michael, et al.
Publicado: (2020)

Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors
por: Bazarbashi, Shouki, et al.
Publicado: (2022)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
por: Bazarbashi, Shouki N., et al.
Publicado: (2016)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017
por: Alsharm, Abdullah, et al.
Publicado: (2018)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre
por: Bazarbashi, Shouki, et al.
Publicado: (2023)

Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
por: Czarnecka, Anna M., et al.
Publicado: (2019)

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
por: Lin, Jingyang, et al.
Publicado: (2023)

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
por: Kraljević, Marija, et al.
Publicado: (2023)

Why local guidelines?
por: Bazarbashi, Shouki
Publicado: (2011)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Adult-Type Ovarian Granulosa Cell Tumour: Treatment Outcomes From a Single-Institution Experience
por: Alhusaini, Hamed, et al.
Publicado: (2022)

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
por: Zhang, Hai-Liang, et al.
Publicado: (2017)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

Saudi Oncology Society clinical management guidelines for renal cell carcinoma
por: Bazarbashi, Shouki, et al.
Publicado: (2011)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
por: Thompson Coon, J S, et al.
Publicado: (2009)

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
por: Kim, Myung Soo, et al.
Publicado: (2018)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Saudi Oncology Society clinical management guidelines development
por: Bazarbashi, Shouki N.
Publicado: (2014)

Surgical and oncological outcome after laparoscopic versus open nephroureterectomy for non-metastatic, upper-tract urothelial carcinoma: A single-centre experience
por: Alothman, Khalid I., et al.
Publicado: (2020)

The Relationship between 25 (OH) D Levels (Vitamin D) and Bone Mineral Density (BMD) in a Saudi Population in a Community-Based Setting
por: Alkhenizan, Abdullah, et al.
Publicado: (2017)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
por: Yildiz, Ibrahim, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h0u95cefoamh2ks874ndoa2j1m